Found: 8
Select item for more details and to access through your institution.
A multicenter phase Ia study of AbGn-107, a novel antibody–drug conjugate, in patients with advanced gastrointestinal cancer.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 2, p. 221, doi. 10.1007/s10637-024-01430-6
- By:
- Publication type:
- Article
The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 2, p. 207, doi. 10.1007/s10637-024-01427-1
- By:
- Publication type:
- Article
Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 2, p. 185, doi. 10.1007/s10637-024-01426-2
- By:
- Publication type:
- Article
PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 2, p. 171, doi. 10.1007/s10637-024-01425-3
- By:
- Publication type:
- Article
First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 2, p. 196, doi. 10.1007/s10637-024-01424-4
- By:
- Publication type:
- Article
Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 2, p. 161, doi. 10.1007/s10637-024-01423-5
- By:
- Publication type:
- Article
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 2, p. 179, doi. 10.1007/s10637-024-01419-1
- By:
- Publication type:
- Article
Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 2, p. 229, doi. 10.1007/s10637-024-01418-2
- By:
- Publication type:
- Article